FIELD: medicine; oncology.
SUBSTANCE: group of inventions relates to the field of medicine, namely to oncology; it is intended for the treatment or prevention of a cancer disease characterized by cancer cells expressing CLDN18.2. A method for the treatment or prevention includes administration to a patient of an antibody having a capability of binding to CLDN18.2 in combination with a chemotherapeutic agent. The chemotherapeutic agent is selected from a group consisting of (i) oxaliplatin and 5-fluorouracil or its prodrug capecitabine, (ii) epirubicin, oxaliplatin, and 5-fluorouracil or its prodrug capecitabine, (iii) 5-fluorouracil or its prodrug capecitabine, folic acid, and oxaliplatin, (iv) irinotecan, (v) docetaxel, (vi) cisplatin, (vii) 5-fluorouracil, and (viii) oxaliplatin. In other embodiments, a medical drug and a kit containing the specified drug are proposed.
EFFECT: use of the group of inventions provides effective treatment or prevention of a cancer disease characterized by cancer cells expressing CLDN18.2.
15 cl, 26 dwg, 1 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
| COMBINED THERAPY WITH CLAUDINE 18.2 ANTIBODIES FOR CANCER TREATMENT | 2014 |
|
RU2699549C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2014 |
|
RU2678700C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| MONOCLONAL ANTI-CLAUDIN-18 ANTIBODIES FOR TREATING CANCER | 2008 |
|
RU2571923C2 |
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER | 2008 |
|
RU2682285C2 |
| ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
